Dabrafenib and Trametinib in Patients With Tumors With BRAF(V600E) Mutations: Results of the NCI-MATCH Trial Subprotocol H

PURPOSE: BRAF(V600) mutations are commonly found in melanoma and thyroid cancers and to a lesser degree in other tumor types. Subprotocol H (EAY131-H) of the NCI-MATCH platform trial sought to investigate the selective BRAF inhibitor dabrafenib and the MEK1/2 inhibitor trametinib in patients with so...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Clin Oncol
Hlavní autoři: Salama, April K. S., Li, Shuli, Macrae, Erin R., Park, Jong-In, Mitchell, Edith P., Zwiebel, James A., Chen, Helen X., Gray, Robert J., McShane, Lisa M., Rubinstein, Larry V., Patton, David, Williams, P. Mickey, Hamilton, Stanley R., Armstrong, Deborah K., Conley, Barbara A., Arteaga, Carlos L., Harris, Lyndsay N., O’Dwyer, Peter J., Chen, Alice P., Flaherty, Keith T.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Clinical Oncology 2020
Témata:
ORIGINAL REPORTS
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7676884/
https://ncbi.nlm.nih.gov/pubmed/32758030
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.20.00762
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky